Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
l�ll
Metformin in cancer therapy: a new perspective for an old antidiabetic drug?Ben Sahra I; Le Marchand-Brustel Y; Tanti JF; Bost FMol Cancer Ther 2010[May]; 9 (5): 1092-9Metformin is the most widely used antidiabetic drug in the world, and there is increasing evidence of a potential efficacy of this agent as an anticancer drug. First, epidemiological studies show a decrease in cancer incidence in metformin-treated patients. Second, metformin decreases insulin resistance and indirectly reduces insulin level, a beneficial effect because insulin promotes cancer cell growth. Third, several reports outline a direct inhibitory effect of metformin on cancer cell growth and an antitumoral action. Finally, metformin activates the AMP activated protein kinase (AMPK) pathway, a major sensor of the energetic status of the cell, which has been proposed as a promising therapeutic target in cancer.|Adenylate Kinase/metabolism/physiology[MESH]|Animals[MESH]|Antineoplastic Agents/pharmacology/*therapeutic use[MESH]|Cell Proliferation/drug effects[MESH]|Humans[MESH]|Hypoglycemic Agents/pharmacology/*therapeutic use[MESH]|Intracellular Signaling Peptides and Proteins/metabolism/physiology[MESH]|Medical Oncology/trends[MESH]|Metformin/pharmacology/*therapeutic use[MESH]|Models, Biological[MESH]|Neoplasms/*drug therapy[MESH]|Protein Serine-Threonine Kinases/metabolism/physiology[MESH]|TOR Serine-Threonine Kinases[MESH] |